Boehringer Ingelheim partners with GNA Biosolutions
Boehringer Ingelheim partners with GNA Biosolutions to develop African swine fever diagnostic test.
Search
TwistPak Mixing platform for swine vaccines
TwistPak® allows for fresh mixing of Ingelvac CircoFLEX® and Ingelvac MycoFLEX® on farm in less than 5 seconds
12th Expert Forum on Farm Animal Well-Being
The 12th Expert Forum on Farm Animal Well-Being brought together over 100 industry experts
Performance Indicators
Performance indicators concerning Environment Health and Safety (EHS) are summarized here.
Boehringer Ingelheim announces collaboration with MabGenesis
Boehringer Ingelheim announces collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine
FreVAX smartphone application piglet vaccination
New FreVAX™ smartphone application brings piglet vaccination to another level
vet scholars symposium
Veterinary students and researchers from 38 veterinary schools in North America and Europe gathered at the NIH in August to discuss the future of veterinary medicine.
Patient centricity and site centricity in clinical trials
We are partnering with patients, caregivers and trial site staff to design and conduct our clinical trials, to provide a better experience for all.
Oncology and Cancer Immunology Research
Find out more about our research and development in oncology and cancer immunology.
What do you know about transboundary animal diseases
Transboundary animal diseases (TADs) are highly transmissible diseases of livestock that can impact veterinary public health preparedness.
biolabs-heidelberg
Boehringer Ingelheim supports the launch of BioLabs first European Location in Heidelberg.
Moving towards a rabies-free Southeast Asia
Boehringer Ingelheim, in collaboration with Eco-Business, has published a comprehensive whitepaper to stop rabies.
NexGard COMBO for cats EMA marketing authorization
Boehringer Ingelheim received marketing authorization from the EMA (European Medicine Agency) for its NexGard® COMBO topical solution for cats.
Breaking prejudice in lung cancer
At Boehringer Ingelheim, addressing patient needs and fighting stigma in lung cancer care are two focus topics of the patient engagement team in oncology.
Aservo EquiHaler wins Pharmapack Award 2021
Boehringer Ingelheim’s Aservo® EquiHaler® is recognized in the 2021 Pharmapack Awards
Mastitis dairy cows prevent antibiotic resistance
The Clinical and Laboratory Standards Institute (CLSI) approved revised interpretive criteria for the susceptibility testing of a mastitis product.
Boehringer Ingelheim partners with PetMedix
Partnering with PetMedix on Ky9™ platform cutting edge technology as a means to bring innovative new therapies to improve health of animals
Boehringer expands production site in Greece
Boehringer expands production site in Greece for new medicine
License to develop new fibro-inflammatory disease treatments
License to develop new fibro-inflammatory disease treatments
Partnership canine oncology
The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
The Supplier Code of Conduct
BI’s expectations towards its suppliers on ethical behavior, integrity, professionalism and common business requirements.
The Goals to Improve Living with GPP
An article that describes the current goals to improve the lives of those living with generalized pustular psoriasis
Partnering with Boehringer Ingelheim at BIO-Europe 2024
Learn about partnering with Boehringer Ingelheim at BIO-Europe 2024 and how together we can accelerate innovation in human health
commitments to sustainable development
On One Health Day, Boehringer Ingelheim shares an update on its strategic approach to sustainability for employees, partners and wider communities
New study paves the way for liver cirrhosis treatments
The ADVANCE study will be the most detailed observational study of its kind providing a detailed analysis of liver health.